{"nctId":"NCT03649477","briefTitle":"Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome","startDateStruct":{"date":"2018-11-20","type":"ACTUAL"},"conditions":["Prader-Willi Syndrome"],"count":130,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"3.2 mg of LV-101","type":"EXPERIMENTAL","interventionNames":["Drug: 3.2 mg intranasal carbetocin"]},{"label":"9.6 mg of LV-101","type":"EXPERIMENTAL","interventionNames":["Drug: 9.6 mg intranasal carbetocin"]}],"interventions":[{"name":"3.2 mg intranasal carbetocin","otherNames":["LV-101"]},{"name":"9.6 mg intranasal carbetocin","otherNames":["LV-101"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Genetically-confirmed Prader-Willi syndrome\n* Provide voluntary, written informed consent (parent(s) / legal guardian(s) of participant); provide voluntary, written assent (participants, as appropriate)\n* PWS Nutritional Phase 3 (hyperphagic, rarely feels full)\n\nExclusion Criteria:\n\n* Living in a group home\n* Genetically diagnosed Schaaf-Yang syndrome or other genetic, hormonal, or chromosomal cognitive impairment\n* New food-related interventions, including environment or dietary restrictions, within 1 month of screening\n* Dose of any allowed chronic concomitant medications or supplements that have not been stable for ≥3 months prior to the study or is not expected to remain stable while participating in the study; adjustments in growth hormone dose ≤10% are not exclusionary\n* Presence of cardiovascular disorders, epilepsy, frequent migraines, or severe asthma\n* More than 3 episodes of sinusitis in the 12 months prior to Screening Visit or presence of nasal diseases that may affect deposition of intranasal medication\n* Unwilling to abstain from nasal saline, other nasal irrigation, or other intranasal medications for 2 weeks prior to the Baseline visit and during the 8-week, placebo-controlled period of the study\n* Use of weight loss medication, oxytocin, carbetocin, or vasopressin in the 6 months prior to screening\n* Participation in an interventional research study involving another investigational medication or device in the 6 months prior to screening or during the study\n* Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to unstable medical condition, inability to comply with the protocol, or other risk to subject or to the integrity of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hyperphagia Behavior","description":"Change in hyperphagia (extreme hunger) as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score versus placebo.\n\nScore range: 0-36; higher scores mean a worse outcome. Reduction in score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.439","spread":null},{"groupId":"OG001","value":"-5.372","spread":null},{"groupId":"OG002","value":"-2.237","spread":null}]}]}]},{"type":"PRIMARY","title":"Obsessive and Compulsive Behaviors","description":"Change in obsessive and compulsive behaviors as measured by the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) Total Score versus placebo.\n\nScore range: 0-40; higher scores mean a worse outcome. Reduction in score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.968","spread":null},{"groupId":"OG001","value":"-3.123","spread":null},{"groupId":"OG002","value":"-2.360","spread":null}]}]}]},{"type":"SECONDARY","title":"Anxiety","description":"Change in participant anxiety as measured by the PWS Anxiety and Distress Questionnaire (PADQ) Total Score versus placebo.\n\nScore range: 0-56; higher scores mean a worse outcome. Reduction in score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.306","spread":null},{"groupId":"OG001","value":"-8.301","spread":null},{"groupId":"OG002","value":"-4.489","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Impression","description":"Clinical Global Impression of Change (CGI-C) score versus placebo. Score range: 1-7; higher scores mean a worse outcome. Reduction in score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.582","spread":null},{"groupId":"OG001","value":"3.395","spread":null},{"groupId":"OG002","value":"3.893","spread":null}]}]}]},{"type":"SECONDARY","title":"Hyperphagia Behavior (Subset)","description":"Change in hyperphagia as measured by the change in specified subsets of HQ-CT questions versus placebo.\n\nScore range: 0-24; higher scores mean a worse outcome. Reduction in score indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.295","spread":null},{"groupId":"OG001","value":"-4.621","spread":null},{"groupId":"OG002","value":"-2.209","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":44},"commonTop":["Flushing","Headache","Epistaxis","Diarrhea","Upper respiratory tract infection"]}}}